Ironwood Pharmaceuticals (NASDAQ:IRWD) Lowered to Hold Rating by StockNews.com

StockNews.com cut shares of Ironwood Pharmaceuticals (NASDAQ:IRWD - Free Report) from a buy rating to a hold rating in a research report sent to investors on Tuesday morning.

IRWD has been the subject of a number of other reports. Leerink Partners reduced their target price on shares of Ironwood Pharmaceuticals from $3.00 to $1.00 and set a "market perform" rating for the company in a report on Monday, April 14th. Craig Hallum reduced their price objective on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Wednesday, January 22nd. JMP Securities decreased their price objective on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a "market outperform" rating for the company in a research report on Thursday, January 30th. Jefferies Financial Group reissued a "hold" rating and issued a $0.70 target price (down previously from $8.00) on shares of Ironwood Pharmaceuticals in a report on Tuesday, April 15th. Finally, Wells Fargo & Company restated an "equal weight" rating and set a $1.00 price target (down previously from $7.00) on shares of Ironwood Pharmaceuticals in a research note on Tuesday, April 15th. Eight analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, Ironwood Pharmaceuticals presently has a consensus rating of "Hold" and an average price target of $4.78.

Ironwood Pharmaceuticals Stock Down 3.3 %

IRWD traded down $0.03 during trading on Tuesday, hitting $0.73. 3,326,562 shares of the stock were exchanged, compared to its average volume of 2,563,595. Ironwood Pharmaceuticals has a 1-year low of $0.59 and a 1-year high of $8.45. The stock has a fifty day moving average price of $1.44 and a two-hundred day moving average price of $3.00. The firm has a market capitalization of $117.31 million, a P/E ratio of -24.17 and a beta of 0.30.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.08). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The business had revenue of $90.55 million for the quarter, compared to analysts' expectations of $93.85 million. Analysts predict that Ironwood Pharmaceuticals will post 0.1 EPS for the current year.

Insider Activity

In other Ironwood Pharmaceuticals news, CEO Thomas A. Mccourt sold 139,064 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $244,752.64. Following the completion of the transaction, the chief executive officer now owns 1,160,634 shares in the company, valued at approximately $2,042,715.84. This represents a 10.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CMO Michael Shetzline sold 41,269 shares of the firm's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $72,633.44. Following the completion of the sale, the chief marketing officer now directly owns 554,007 shares of the company's stock, valued at approximately $975,052.32. This trade represents a 6.93 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 192,381 shares of company stock valued at $338,591 in the last three months. 12.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in IRWD. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter worth approximately $36,000. Journey Strategic Wealth LLC purchased a new stake in Ironwood Pharmaceuticals during the fourth quarter worth $45,000. Simplicity Wealth LLC acquired a new stake in Ironwood Pharmaceuticals in the first quarter valued at $45,000. Catalyst Funds Management Pty Ltd purchased a new position in shares of Ironwood Pharmaceuticals in the fourth quarter valued at $47,000. Finally, Xponance Inc. acquired a new position in shares of Ironwood Pharmaceuticals during the 4th quarter worth $50,000.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.